Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

MolDX lists breast-cancer MRD coverage for neoadjuvant disease and for recurrence in advanced disease

The MolDX billing article A58434, in the revision effective January 1, 2026, lists Signatera for neoadjuvant breast cancer and lists NeXT Personal, Pathlight, RaDaR, and Signatera for recurrence or relapse testing in advanced breast cancer.

CMS MolDX